Exacerbations in {alpha}1-antitrypsin deficiency

scientific article published in June 2005

Exacerbations in {alpha}1-antitrypsin deficiency is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1183/09031936.05.00074704
P698PubMed publication ID15929953
P5875ResearchGate publication ID7812078

P2093author name stringM Needham
R A Stockley
P433issue6
P304page(s)992-1000
P577publication date2005-06-01
P1433published inEuropean Respiratory JournalQ12257435
P1476titleExacerbations in {alpha}1-antitrypsin deficiency
P478volume25

Reverse relations

cites work (P2860)
Q38092905Airway disease in alpha-1 antitrypsin deficiency
Q39450745Alpha-1 Antitrypsin Deficiency: Phenotypes and Quality of Life
Q64974062Alpha-1 Antitrypsin Substitution for Extrapulmonary Conditions in Alpha-1 Antitrypsin Deficient Patients.
Q38092880Alpha-1 antitrypsin deficiency: the European experience
Q37986292Alpha-1 antitrypsin: a potent anti-inflammatory and potential novel therapeutic agent
Q38937853An ECLIPSE View of Alpha-1 Antitrypsin Deficiency
Q40980393Antitrypsin Deficiency Assessment and Programme for Treatment (ADAPT): The United Kingdom Registry
Q28392320Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approach
Q37362591Augmentation therapy for emphysema due to alpha-1-antitrypsin deficiency
Q91671206Comparing Patients with ZZ Versus SZ Alpha-1 Antitrypsin Deficiency: Findings from AlphaNet's Disease Management Program
Q64986349Decline in FEV1 and hospitalized exacerbations in individuals with severe alpha-1 antitrypsin deficiency.
Q33713789Deterioration of quality of life is associated with the exacerbation frequency in individuals with alpha-1-antitrypsin deficiency - analysis from the German Registry.
Q37780552Emerging drugs for alpha-1-antitrypsin deficiency
Q57175296Health status decline in α-1 antitrypsin deficiency: a feasible outcome for disease modifying therapies?
Q46303528Inhaled alpha 1-antitrypsin: gauging patient interest in a new treatment
Q33743024Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence
Q36275067Patterns and characterization of COPD exacerbations using real-time data collection
Q23911017Rationale and design of the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis. Alpha-1 protocol
Q36444197Relationship between frequency, length, and treatment outcome of exacerbations to baseline lung function and lung density in alpha-1 antitrypsin-deficient COPD.
Q51073341Relationship of the 2011 Global Initiative for Chronic Obstructive Lung Disease strategy to clinically relevant outcomes in individuals with α1-antitrypsin deficiency.
Q36379352Role of infection and antimicrobial therapy in acute exacerbations of chronic obstructive pulmonary disease
Q37303247Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency.
Q37362027The parallel lives of alpha1-antitrypsin deficiency and pulmonary alveolar proteinosis
Q47703811Therapeutics: Alpha-1 Antitrypsin Augmentation Therapy
Q48076378Usefulness of the CAT, LCOPD, EQ-5D and COPDSS scales in understanding the impact of lung disease in patients with alpha-1 antitrypsin deficiency
Q83079365[Augmentation therapy with alpha-1 antitrypsin: 20 year- follow-up of a deficient patient]

Search more.